Ferroptosis is a type of cell death that related to cancer, however, the characteristics of ferroptosis in cancers are still uncertain. Based on the data in The Cancer Genome Atlas, we found that most ferroptosis regulator genes (FRGs) were differentially expressed in tumors, copy number alterations (CNA) and DNA methylation contributed to their aberrant expression. We established the ferroptosis potential index (FPI) to reveal the functional roles of ferroptosis and noticed that the FPI was higher in tumors than in normal tissues in most cancers, and was associated with subtypes and clinical features. The FPI was negatively correlated with several metabolism pathways but positively associated with several important metastasis-related pathways and immune-related pathways.
cancers will be helpful.
In the present study, for the first time, we performed a comprehensive analysis of genomic variations and expression profiles of the FRGs across 20 cancer types. Furthermore, we computationally modelled the ferroptosis level based on FRGs expression, and dissected the relations between ferroptosis and cancer clinical features. It was found that ferroptosis was associated with various cancer hallmarks, immune microenvironment, drug resistance and patient survival.
These results highlighted the critical roles of ferroptosis in cancer and should be helpful for further investigations of ferroptosis-related molecular mechanisms and therapy development.
Materials and Methods

Datasets and Source
The mRNA expression data, copy number alteration thresholded data, masked copy number segmentation data, and DNA methylation 450K data of twenty cancers, including bladder urothelial Additional gene-centric RMA-normalized gene expression profiles and drug response data of over 1000 cancer cell lines were accessed from the Genomics of Drug Sensitivity in Cancer (GDSC) database (https://www.cancerrxgene.org/downloads) [21] . Immune associated data, including immune cell type fractions and immunophenoscore were obtained from TCIA (https://tcia.at/home) [22] . Integrated protein-protein interaction data was obtained from the Human Protein Reference Database (http://www.hprd.org/) and BioGRID (https://thebiogrid.org) [23, 24] . We obtained clinically actionable genes (CAGs) from a previous study [25] (https://software.broadinstitute.org/cancer/cga/target).
Differential expression analysis of mRNA
To test genes differentially expressed between tumor and normal tissue, gene expression data for 20502 genes across 20 cancer types were downloaded from TCGA at FireBrowse (http://gdac.broadinstitute.org, 2016 January). Then, the fold change and adjusted P-value were calculated by the edgeR package [26] . We defined genes with an adjusted P-value less than 0.05 as the differential expression genes (DEGs).
Establishing the Ferroptosis Potential Index Model
The enrichment score (ES) of gene set that positively or negatively regulated ferroptosis was calculated using single sample gene set enrichment analysis (ssGSEA) in the R package 'GSVA' [27] , and the normalized differences between the ES of the positive regulation gene set minus negative regulation gene set was defined as the ferroptosis potential index (FPI) to computationally dissect the ferroptosis levels/trends of the tissue samples.
Somatic Copy-number Alteration (SCNA) and Mutation Analysis
The heterozygosity and homozygosity of amplification and deletion were included to elevate the copynumber alteration of each gene, in which over five percent was regarded as high-frequency SCNA.
Pearson's correlation between expression values and copy number segment values of each gene
was calculated to evaluate the association between CNA and expression. The R package "DISCOVER" was employed to evaluate mutual exclusivity between FRGs and tumor suppressor genes or oncogenes across tumor samples in each cancer type [28] . The mutation and CNA events were integrated, while only homozygous amplification and deletion were included, and only proteincoding mutations were retained. For each cancer type, the genes were considered to be mutually exclusive if they had a q value of 0.05.
DNA methylation analysis
The R package "IlluminaHumanMethylation-450kanno.ilmn12.hg19" from Bioconductor was imported to annotate the methylation probe for the promoter of each gene. Differential methylation of each gene in tumor and normal samples was tested by the Wilcoxon signed rank test, and genes that were significantly hypomethylated or hypermethylated were identified using a P-value cutoff of 0.05.
Pearson's correlation between the transcriptional expression of FRGs and the Beta value of the promoter DNA methylation were calculated and considered significant if the P-value < 0.05.
miRNA expression analysis
To investigate the mechanisms of dysregulation for ferroptosis regulator genes in cancer, we searched potential miRNAs which might regulate the FRGs based on miRNA-target intersections in starBase.
The Spearman correlation between the expression of miRNA and FRGs was statistically evaluated (adjusted P-value < 0.1, rho < -0.1). Cytoscape software was used to visualize the high-frequency interaction networks among FRGs and miRNA [29] .
Multivariate Regression Analysis of Gene Expression
To assess which factors had significant effects on FRG expression, the expression of each FRG was modeled by linear regression as a function of the median miRNA expression, the median Beta value of promoter methylation, and the copy number of the genes.
Clinical Features Analysis
The R package "survival" was used to assess the prognosis potential of the FRGs and ferroptosis potential index among cancers. For survival analysis, the expression threshold was exhaustively tested and the one with most significant P-value was considered the best cut-off. To test the association between ferroptosis level and clinical features, the Pearson correlation was calculated between FPI and tumor stages, age, body mass index (BMI) and cigarette exposure per day, which were converted to numeric variables ("stage1" = 1, "stage2" = 2, etc.). Wilcoxon rank sum tests and Tukey's tests were used to determine the impact on the ferroptosis potential index for other clinical characteristics including race, remission status, and alcohol. The influence of different MSI statuses, histologic types, and molecular subtypes on FPI were also considered.
Immune Features Analysis
To study the relationship of ferroptosis and immune microenvironments, we computed the Pearson correlation between FPI and immune parameters including immune cell fractions and 5 types of immunophenoscores.
Identifying the FPI associated significant driver gene mutation
A total of 375 driver genes identified in previous pan-cancer research were included for analysis [30] .
To test whether a driver gene's mutational status was significantly associated with ferroptosis among cancers, the rank-transformed FPI was modeled by linear regression as a function of the driver gene's mutational status, ignoring the synonymous variant. To diminish the confounding effects, the ranktransformed count of the total nonsynonymous mutations and the tumor type, which were encoded as virtual variables, were included. To further characterize each cancer, the Benjamini-Hochberg method was used to correct the P values across 375 genes. Genes with an adjusted P value less than 0.05 for mutation status variable were significantly associated with FPI.
Gene Set Enrichment Analysis
To identify the pathways associated with ferroptosis, the samples of each tumor type were divided into two groups according to the FPI, consisting of the top 30% and bottom 30%. Then, the gene set enrichment analysis (GSEA) was performed [31] .
Correlation between Drug Sensitivity and FPI/FRG Expression
To test the correlation between small molecular drugs and FPI and FRGs, the Pearson correlation coefficients for FPI, the expression value of FRGs and the area under the dose-response curve (AUCs) values were calculated, the results with |R| > 0.1 and P-value < 0.05 were considered as significantly correlated. To further investigate the influence of drugs on ferroptosis, the significant association between the expression of clinically actionable genes and FRGs were finished across cancer cell lines, and the associations were filtered with PPIs. Then the drugs which target CAGs were selected according to DrugBank [32] (https://www.drugbank.ca).
Results
Genetic alterations of ferroptosis regulator genes (FRGs) in cancers
In this study, we defined the 24 genes including CDKN1A, HSPA5, TTC35, SLC7A11, NFE2L2, MT1G, HSPB1, GPX4, FANCD2, CISD1, FDFT1, SLC1A5, SAT1, TFRC, RPL8, NCOA4, LPCAT3, GLS2, DPP4, CS, CARS, ATP5G3, ALOX15, and ACSL4, as ferroptosis regulator genes (FRGs), which were identified to play critical roles in regulating ferroptosis by previous studies [2] . To determine the patterns for dysregulation of FRGs in cancer, we examined the genomic data, including genetic variation, somatic copy number alternation (SCNA), mRNA expression and DNA methylation data of tumor and normal tissues from 20 cancer types. The analysis of nonsynonymous mutations in 20 cancer types showed that the mutation frequencies for FRGs were generally low ( Figure S1A ), while 13 FRGs in UCEC had mutation frequencies greater than 5%. Furthermore, NFE2L2, which encodes NRF2 and plays a master regulator role in anti-oxidant responses and has been shown to cause resistance to ferroptosis [11], showed relatively high mutation frequencies in multiple cancers compared to other FRGs.
To further dissect the genetic aberrance of FRGs in cancer, the percentage of SCNA was examined and the results showed that in general SCNA occurred at high frequencies (with over five percent of all samples) in most cancer types ( Figure 1A ), but all FRGs in THCA showed a low frequency of SCNA. It was observed that FRGs presented diverse SCNA profiles. For example, TTC35, HSPB1, TFRC, and RPL8 were more prone to copy number gain than copy number loss in almost all tumors, but SCL7A11 and ALOX15 showed the opposite profile. Furthermore, we analyzed the co-occurrence of mutations and SCNA between FRGs and oncogenes/tumor suppressor genes (TSGs) previously identified by Bailey et al. [33] . The significance was calculated via the mutual exclusivity test by DISCOVER [28], with a false discovery rate of 1%. A total of 28 oncogenes ( Figure   S1B ) and 43 TSGs ( Figure S1C ) were found to be altered with FRGs in the mutually exclusive manner in certain cancer types, and FDFT1, RPL8, TFRC, and NFE2L2 were frequently exclusive to oncogenes or TSGs (Figure S1B-C).
Aberrant expression of FRGs among cancer
Besides genetic alternations, differential expression analysis was performed to investigate alteration of gene expression patterns of FRGs, and the numbers of tumor and normal sample were showed in Table 1 . We found that all FRGs were differentially expressed in at least one cancer type.
Several FRGs showed consistent expression patterns in cross-cancer analysis. SLC7A11, FANCD2, CARS, SLC1A5 and RPL8 were significantly upregulated in 15, 18, 12, 15, 14 types of cancers, respectively, while NCOA4 was downregulated in 15 cancers ( Figure 1B) . Additionally, several FRGs showed miscellaneous cancer type specificities which has not been well characterized previously. For example, HSPA5 was upregulated in most cancer types including breast invasive carcinoma (BRCA) (fold change [FC] = 1.87, adjust P-value = 1.42 ×10 -42 ) and LUAD (FC = 1.90, adjust P-value = 2.45 ×10 -29 ) but was significantly downregulated in THCA (FC = 0.68, adjust P-value = 2.67 ×10 -7 ). DPP4, which appears to play a suppressor role in the development of cancer [34] [35] [36] , showed significant upregulation in KIRC, KIRP, ESCA, LUAD, GBM, and THCA, but was downregulated in CHOL, KICH, BRCA, LUSC, HNSC, and STAD. We also noticed that DPP4 had opposed expression profiles in different subtypes of tumors in the lung and kidney. This demonstrated that FRGs might play different roles in different cancers.
Since SCNA in tumors plays a critical role in regulating gene expression, we evaluate the effects of SCNA on gene expression of FRGs. The Pearson correlation between gene expression and the copy number from masked copy number segment of TCGA was examined. The results showed that the expression of most FRGs was obviously correlated to SCNA in most tumors ( Figure 1C ). For example, the expression of citrate synthase (CS), which participates in oxidative metabolism, was significantly associated with SCNA in all cancer. This result indicates that the aberrance of copy number for FRGs is common in most cancers and can have an influence on gene expression.
Besides SCNA, the methylation of promoter can regulate gene expression, and aberrant DNA methylation of the promoter is associated with tumorigenesis [37] . We observed that FRGs showed complex methylation patterns in the 20 cancer types ( Figure 1D ), only CDKN1A showed hypomethylation in 11 tumors consistently. For example, we observed that DPP4 showed hypermethylation in seven cancer types and hypomethylation in four cancer types. Although there were differences in the pattern of methylation for FRGs, a negative relationship was observed between gene expression and DNA methylation overall ( Figure 1E ). This result demonstrated that promoter DNA methylation may regulate the expression of FRGs in tumors.
Besides SCNA and DNA methylation, microRNAs (miRNAs) can regulate gene expression and become involved in cancer development [38] . To determine which miRNAs are involved in regulating ferroptosis, we performed the analysis to reveal the network of miRNA-FRGs. The starBase database was used to infer miRNA that potentially targeting FRGs, and those miRNAs that were significantly negatively correlated with gene expression were thought to be involved in the regulation of FRGs [39] .
As the network showed ( Figure 1F ), all of the interactions between miRNA and FRGs occurred in more than six cancers. It is obvious that FRGs could be targeted by miRNA with high frequency,
including ACSL4, NCOA4, and CDKN1A ( Figure 1F ). To further understand the aberrances of the miRNA-FRG network in tumors, we conducted differential expression analysis of miRNA and counted the expression aberrances of miRNA across cancer types ( Figure S1D ). It was found that several miRNAs had consistent expression trends in tumors, for example, has-miR-93 targeted CDKN1A and was downregulated in 11 cancers. On the other hand, miRNA had different expression trends in different tumors. For example, has-miR-375 targeted ACSL4 in five tumors, but it showed upregulation in two cancers and downregulation in three cancers. This suggests that miRNA play a regulatory role in FRGs expression, and the aberrant expression of miRNA in the tumors could impact ferroptosis.
Since SCNA, DNA methylation, and miRNA all can regulate FRGs expression, but the contribution of a single factor on gene expression is not clear. The linear regression approach was applied to analyze the contribution of each factor and diminish the confounding effects. As the results showed ( Figure S1E ), SCNA was positively correlated with gene expression, while methylation and miRNA showed a negative correlation. We further observed multiple regulated patterns in FRGs, and the expression of several FRGs was only related to a single factor in several tumors, while others were related to multiple factors. For example, ACSL4 expression was only associated with miRNA in seven cancers, including BLCA, CESC, KIRC, KIRP, LUAD, PRAD, and UCEC. SCNA played the only significant regulator role for CARS in CHOL, ESCA and colorectal cancer. However, the expression of NCOA4 and NFE2L2 was significantly regulated by three factors in seven and ten tumors, respectively. Thus, all the FRGs show diverse regulation patterns in different cancers. This suggests that the expression regulation patterns of all FRGs were tumor-specific.
Computational modeling the ferroptosis level among cancers
To further understand the role of ferroptosis in tumorigenesis and investigate the factors or biological processes associated with ferroptosis, the ferroptosis potential index (FPI) was modeled based on the enrichment score (ES) of positive regulatory components calculated by ssGSEA minus that of negative regulatory components. We performed multiple analyses to validate the performance of FPI and test the robustness of this index. First, we collected three independent gene expression datasets of tumor cell lines that were treated with erastin or withaferin A (WA), which were reported as an inducer of ferroptosis [1, 40] , or ferrostatin that was identified as an inhibitor of ferroptosis [41].
The FPI was calculated and analyzed for the gene expression datasets in neuroblastoma cells (GSE112384), clear cell carcinoma cells (GSE121689) and liver cancer cells (GSE104462) ( Figure   S2 ). The results showed that erastin and WA increased the FPI remarkably in all of this three cell lines, while ferrostatin could slightly decreased the FPI compared to control group ( Figure S2A, S2D,   S2G ). Because the increases of the CHAC1 and PTGS2 mRNA and ACSL4 protein were associated with cells undergoing ferroptosis, but these changes were not consistent in all experiments [2] , we compared the mRNA expression of these three genes in this three cell lines. There were no significant changes in PTGS2 and ACSL4 but CHAC1 was upregulated after treated with erastin or WA ( Figure   S2B , S2E, S2H). Then we examined Pearson's correlation between FPI and the mRNA expression value of CHAC1, as the results showed ( Figure S2C , S2F, S2I) they were significantly highly associated and all of coefficient were over 0.7. Thus, the FPI could be used to represent the potential level of ferroptosis based on the transcriptome data.
Based on the computed marker of ferroptosis, we compared the differences of FPI between tumor and normal tissues with the cancer genome atlas (TCGA) data (Figure 2A ). Of note, significant differences were found in most cancers such as lung cancer and gastrointestinal cancer, and higher FPI was observed in most tumors except for BRCA and UCEC. We also noticed that the FPI of normal tissues was higher than tumors in female cancers (BRCA, UCEC, and CESC). To further dissect the factors involved in these different FPI patterns, we examined the FPI for different subtypes of BRCA.
The results presented in Figure 2B showed that all the estrogen receptor (ER)-positive, progesterone receptor (PR) positive and HER2 positive patients had lower FPI than the negative patients, respectively. Furthermore, triple negative breast cancer (TNBC) samples showed higher ferroptosis level than non-TNBC samples ( Figure 2C) , which was consistent with previous study [42] .
Furthermore, among the different subtypes of kidney cancer, the FPI of tumor samples was higher than normal in KIRP and KIRC, while the FPI in KICH was lower (Figure 2A ). In addition, to further dissect the variances of ferroptosis level in different histological types, the FPI in the esophagus squamous cell carcinoma (ESCC) and esophagus adenocarcinoma (ESAD) were compared. The results showed that FPI in ESCC was significantly higher than ESAD and normal samples, while ESAD was higher than normal but not significant ( Figure 2D ).
Besides the cancer types and subtypes, we analyzed the correlation between the FPI and remarkable molecular features such as microsatellite instability (MSI) and driver gene mutations. The FPI decreased obviously in tumors with high-level of MSI (MSI-H) compared to non-MSI-H tumors in gastrointestinal tumors ( Figure 2E ). The FPI was remarkably lower in COAD and STAD patients with MSI-H, and slight decrease was also observed in ESCA and READ ( Figure 2F ). Furthermore, we analyzed the correlation between FPI and 375 driver genes that frequently mutated in tumors based on regression-based analysis. Through controlling for cancer type and tumor mutation burden (TMB), 81 genes were found to be correlated, and most of them were negatively associated with FPI (adj.p < 0.1, Figure S3A ). Strikingly, somatic mutations, namely NFE2L2, BRAF, and TP53, were positively associated with FPI in pan-cancer associations, but a mutation in TP53 was negatively correlated with ferroptosis in LUSC. This observation was verified by the comparison of FPI between the TP53 mutant and wild type groups ( Figure S3B ), consistent with previous finding that showed that TP53 played a dual role in regulating ferroptosis [43] . The influences of KRAS mutations on FPI were also investigated, and the results showed that KRAS mutations had a significantly negative effect on ferroptosis in gastric tumors ( Figure S3C ), and we observed that KRAS mutations positively impacted FPI in hepatocellular carcinoma ( Figure S3A, S3C ). Furthermore, the differential expression of FRGs between wild type and mutant tumors for TP53 ( Figure S3D ) and KRAS ( Figure S3E ) were found to be ubiquitous in most cancers. Taken together, ferroptosis was negatively related with MSI-H in cancer.
Association between ferroptosis and pathways in cancer
To further elucidate the related cellular signaling of ferroptosis in cancer, gene set enrichment analysis (GSEA) was performed based on the transcriptome of two tumor groups with the top and bottom thirty percent of FPI. It was observed that metabolism related pathways in KEGG usually enriched in the tumor with lower FPI, and pathways frequently enriched (>6 cancers) were presented in Figure 3A . For example, terpenoid backbone biosynthesis and steroid biosynthesis were enriched in the low FPI group in 19 and 16 cancers, respectively ( Figure 3A) . Peroxisome, biosynthesis of unsaturated fatty acids, etc. were also significantly correlated with lower FPI in many cancer types ( Figure 3A) . Furthermore, the relations between cancer hallmarks and FPI were also analyzed, and the results showed that 15 hallmarks were frequently significantly correlated with FPI ( Figure 3B ). For example, KRAS signaling, epithelial-mesenchymal transition, IL6 JAK STAT3 signaling, WNT Betacatenin signaling were enriched in the high FPI group, which indicated that ferroptosis was positively related with these oncogenic pathways ( Figure 3B ). Also, metabolism related hallmarks were observed to be negatively related with ferroptosis, which was consistent with the pathway analysis ( Figure 3B ).
Since previous studies showed that ferroptosis was related to the immune response process [5] , here we investigated the association between ferroptosis and immune microenvironment in tumor.
The results showed that in several cancers FPI was weakly negatively correlated with immunophenoscore (IPS) ( Figure 3C ), which could predict the response of the immune checkpoint blockade in melanoma tissue [22] . Furthermore, FPI was positively correlated with MHC and effector cells (EC) but negatively correlated with immunomodulators (CP) and suppressor cells (SC) in most cancers ( Figure 3C ). The associations between ferroptosis and immune cell types were further evaluated in detail, and the results showed that FPI showed a positive correlation with macrophages in most cancers and a negative association with the activated dendritic cells, activated mast cells, plasma cells and T follicular helper cells ( Figure S4A ). Thus, there might be close connections between ferroptosis and immune microenvironment, and more investigations were needed to reveal the details.
Clinical relevance of ferroptosis and its regulators
Since ferroptosis was involved in cellular metabolism and immune microenvironment, it was proposed that ferroptosis and its regulators should be correlated with cancer survival and other clinical characteristics. Based on the clinical data from TCGA, the survival analysis was performed and the results were consistent since it is found that the lower FPI predicted a better survival in five cancers including GBM, KIRC, KIRP, LIHC, and LUAD (Figure 4 ). We further dissected the factors that might impact FPI including tumor stage, cigarette smoking, age, and gender. As the results shown ( Figure   S4B ), tumor stages were positively correlated with FPI in LIHC, KIRC, KIRP, and COAD. Only the FPI in LUAD tumors showed a positive correlation with cigarettes smoked per day. Age was positively associated with FPI in GBM and PRAD but showed a negative correlation in seven cancers such as BRCA and LIHC. It was observed that FPI was remarkably different between genders ( Figure S4C ), FPI for females was higher than males in KIRC, LIHC, LUAD, and LUSC, but lower in STAD.
Significant difference in FPI were also observed among different races in BLCA, BRCA and ESCA.
Furthermore, we found that the FPI was correlated cancer metastasis, recurrence, primary and follow outcome in several cancers. In addition, we evaluated the association between FPI and other clinical characteristics including alcohol abuse, fatty liver, hemochromatosis, and viral infection (HPV, HBC, HCV, and EBV), while no significant results were observed. These results indicate that ferroptosis might play critical roles in cancer survival, and clinical factors have tumor-specific effects on FPI.
To further dissect the clinical relevance of ferroptosis in cancer, the roles of FRGs in cancer survival were analyzed. The survival analysis showed that all FRGs were associated with overall survival in at least six cancer types ( Figure S4D ), but the correlations were miscellaneous since most FRGs could both serve as protective and risk factors in different cancers. For example, patients with higher expression of FANCD2 showed better survival in kidney cancer, LIHC, and LUAD, but showed worse survival in READ, STAD, and BLCA ( Figure S4D ). However, high expression of CARS and MT1G showed consistent better survival among cancers including KICH, UCEC, PAAD, and HNSC ( Figure S4D) . Thus, the functional roles of FRGs in cancer survival should be further explored.
To study the potential clinical implications of ferroptosis, we examined the association between the gene expression of FRGs and 156 clinically actionable genes (CAGs), including 136 genes for targeted therapy and 20 genes for immunotherapy across cancer types [25, 44] . As a FRG, CDKN1A
regulates iron uptake and GPX4 abundance [2] , was also a CAG targeted by anti-cancer drugs, such as the inorganic compound arsenic trioxide [45] . We found that all 136 CAGs and FRGs had significant co-expression relationships that were significantly different across cancers as shown in Figure S5A . The number of CAGs correlated with FRGs ranged from 45 in LUSC to 132 in THCA ( Figure S5B) . The FRG-CAG correlation pairs ranged from 69 in LUSC to 581 in THCA ( Figure S5C ).
For example, GPX4 co-expressed with MAP2K2 in 20 cancer types, and showed a significantly positive correlation with TNFRSF4, which are targeted genes for immunotherapy. ACSL4 is significantly correlated with 17 of 20 genes targeted for immunotherapy, suggesting that ACSL4 has a potential effect on cancer immunotherapy ( Figure S6A ). Furthermore, besides co-expression, the protein-protein interactions among drug-targeted CAGs and FRGs were analyzed, and the results presented in Figure S6B showed that the interactions were obvious. For example, EGFR, the target of lapatinib, gefitinib and afatinib, was positively associated with FRGs including DPP4 (R = 0.15) and
HSPA5 (R = 0.31), and negatively correlated with FDFT1 (R = -0.24), while there were protein-protein interactions between EGFR and DPP4, HSPA5, FDFT1 ( Figure S6B ). These results indicated that ferroptosis might be involved in drug effects by interacting with targeted clinically actionable genes.
Taken together, our studies suggest that clinically actionable genes are closely related to FRGs, which highlights the significance of ferroptosis in cancer treatment, including both immunotherapy and targeted therapy.
To further understand the correlation between ferroptosis and drug sensitivity, the area under the percent viability curve (AUC) approach was employed to evaluate drug sensitivity [46] and calculate the correlation between FPI and drug sensitivity across cancer cell lines. Drugs associated with FPI were also tested for their correlation with FRG expression. We identified that FPI was significantly associated with 64 drugs, including 12 that were negatively correlated and 52 that were positively correlated ( Figure S6C ). To explore the effects of each FRG on drug sensitivity, we also analyzed the associations between the drug sensitivity of 64 cancer drugs and the expression of FRGs, and found 521 significantly correlated pairs ( Figure S6C ). Among them, the expression of FANCD2 was correlated with AUC in 57 drugs, while no significant relation was observed for CISD1 ( Figure S6C ).
Furthermore, the associations classified the FRGs into two group, one group included genes such as FANCD2 and ATP5G3, which were positively associated AUC of docetaxel, trametinib, etc. ( Figure   S6C ). The other group included SLC7A11, SAT1, HSPA5, etc., which were negatively associated ( Figure S6C ). Taken together, these results suggest that ferroptosis was correlated to the sensitivity of multiple drugs.
Discussion
Ferroptosis is driven by damage of cell membranes caused by the loss of activity of GPX4 [47] .
Researchers identified that ferroptosis is closely related to tumorigenesis and plays an important role in cancer treatment [4, 48] . However, there is a lack of systematic studies on ferroptosis and its regulator genes across cancer types. In this study, we employed multi-omics data and clinical data across 20 cancer types from TCGA and revealed the global alterations of ferroptosis regulator genes at genetic, epigenetic and transcriptional levels. We also used ssGSEA to process expression data to establish FPI to characterize ferroptosis and addressed which genetic and nongenetic factors (including drug and patient phenotype) were related with FPI. Different molecular types affected the ferroptosis in breast cancer and gastrointestinal cancer, which meant that the responses of different molecular subtypes to treatment may be related to ferroptosis. On the other hand, molecular subtypes need to be considered when ferroptosis is applied as a therapeutic strategy.
The mechanism by which ferroptosis regulates tumor cell growth and proliferation is still unclear, but the relationship we observed between FPI and hallmarks of cancer could improve the understanding the role of ferroptosis. The results of GSEA demonstrate that the level of ferroptosis is closely related to tumor-associated hallmarks in most cancers. Ferroptosis genes can play both oncogene and tumor suppressor roles in cancer [43] , and the FPI acts as a protective or risk factor across cancer types. We also found that several common clinical factors affected ferroptosis, such as cigarette smoking, BMI and tumor stage. As we know, cigarette smoking is a risk factor for esophageal cancer, lung cancer and kidney cancer [49] [50] [51] . In our results, the number of cigarettes per day was positively correlated with the ferroptosis potential index in LUAD, which may be because the cigaretteinduced oxidation reaction promoted lipid peroxidation [52] [53] [54] . FPI also varied between the sexes in several cancers, including LIHC, LUAD, LUSC, and STAD and between different races in BRCA, BLCA, and ESCA, which implied that gender and race need to be considered when using ferroptosis as a treatment strategy. We also noticed that better clinical outcomes or status in several cancer types also have lower FPI, which further confirmed the dual role of ferroptosis. Thus, a different strategy of regulating the ferroptosis of tumor cells may benefit patients and improve prognosis.
Furthermore, we showed that FRGs were co-expressed with most clinically actionable genes and interacted with genes modulated by drugs, suggesting that studying ferroptosis may improve the strategy for cancer therapy. We observed that the co-expression of FRGs and CAGs could be roughly divided into two groups, and drugs that target clinical genes could have complex regulatory effects on ferroptosis. Most strikingly, the expression of GPX4 was associated with MAP2K2 in 20 cancers, which indicated that MAP2K2 may play an important role in ferroptosis. To further explore drug sensitivity and ferroptosis, we observed that the FPI could characterize the sensitivity of many drugs, the AUC of many drugs was inversely associated with the FPI in cancer cell lines, which implied that regulating the ferroptosis of tumor cells may improve the therapeutic effect of cancer treatments.
However, opposite effects were observed regarding the effects of drugs on ferroptosis. Thus, further detailed studies should be carried out to determine the functions and mechanisms of ferroptosis in different cancers.
Conclusions
In the present study, we presented a systematical analysis of ferroptosis and its regulator genes across cancers. Most FRGs were aberrantly expressed in tumors among various cancer types, while frequent CNA and differential DNA methylation contributed greatly. We established the FPI to evaluate the ferroptosis level and found that the FPI were higher in tumors than in the adjacent normal tissues in most cancers and were associated with clinical features, and cancer metastasis, recurrence, outcome and drug sensitivity. These findings highlighted the potential of ferroptosis-based cancer therapy. Table   Table 1 -The abbreviations and numbers of samples for the 20 types of tumors investigated in this study. correlation between FPI and the expression of well-known FRGs including PTGS2 (B), ACSL4 (C), CHAC1 (D) and driver genes (E).
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Additional Figure S3 -The correlation between the FPI and mutation status of driver genes (A). The FPI between mutant and wild type tumors for TP53 (B) and KRAS (C). The differential expression of FRGs between mutant and wild type tumors for TP53 (D) and KRAS (E).
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